Akero Therapeutics Long-Term Debt 2011-2026 | AKRO

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Akero Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
529 K	819 K	1.08 M	1.31 M	1.52 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.52 M	529 K	1.05 M

Quarterly Long-Term Debt Akero Therapeutics

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
289 K	372 K	529 K	605 K	679 K	819 K	888 K	-	1.02 M	1.08 M	1.14 M	-	1.26 M	1.31 M	1.36 M	1.42 M	1.47 M	1.52 M	1.52 M	1.52 M	1.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.52 M	289 K	1.07 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	130 K	$ 1.06	-0.93 %	$ 5.78 M	China
Autolus Therapeutics plc AUTL	47.9 M	$ 1.82	-4.85 %	$ 464 M	Britain
Adagene ADAG	417 K	$ 1.65	-	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	59.9 K	$ 3.45	3.6 %	$ 8.3 B	Australia
Arrowhead Pharmaceuticals ARWR	104 M	$ 64.9	-0.15 %	$ 8.68 B	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	13.2 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Biogen BIIB	6.3 B	$ 187.4	0.75 %	$ 27.3 B	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
BioXcel Therapeutics BTAI	103 M	$ 1.98	-1.0 %	$ 5.02 M	USA
AlloVir ALVR	16.6 M	-	4.14 %	$ 49.1 M	USA
CASI Pharmaceuticals CASI	1.1 M	$ 1.04	-2.34 %	$ 142 M	USA
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Catalyst Biosciences CBIO	199 K	$ 10.74	-2.1 %	$ 707 M	USA
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	14.7 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	8.76 M	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
AIkido Pharma AIKI	2.63 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	2.36 M	$ 27.0	-1.28 %	$ 1.74 M	USA
Cellectis S.A. CLLS	28.8 M	$ 4.42	-1.34 %	$ 116 M	France
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
BioVie BIVI	275 K	$ 1.27	-2.31 %	$ 1.88 M	USA
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	19.9 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	231 M	$ 99.81	0.97 %	$ 27.2 B	Germany
AVROBIO AVRO	188 K	-	1083.1 %	$ 745 M	USA
Amphastar Pharmaceuticals AMPH	614 M	$ 27.75	0.02 %	$ 1.34 B	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	627 M	$ 11.13	-2.02 %	$ 720 M	USA
BioDelivery Sciences International BDSI	78.5 M	-	-4.8 %	$ 255 M	USA
Axon Enterprise AXON	41.4 M	$ 633.45	3.34 %	$ 48 B	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	10.9 M	$ 2.64	-0.75 %	$ 16.6 M	USA
BeiGene, Ltd. BGNE	166 M	-	0.49 %	$ 251 B	Cayman-islands
AstraZeneca PLC AZN	17.5 B	$ 94.65	0.68 %	$ 96.9 B	Britain
Bellicum Pharmaceuticals BLCM	25.7 M	-	-9.72 %	$ 5.89 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA